Core Viewpoint - Chongqing Huason Pharmaceutical Co., Ltd. has received approval from the National Medical Products Administration for clinical trials of HSN002066C1 tablets, marking a significant milestone in the company's innovative drug development [1][2]. Group 1: Drug Approval and Development - HSN002066C1 tablets, a selective PARP7 inhibitor, are developed by Huason Yingnuo and are intended for the treatment of advanced malignant solid tumors [1]. - The drug has shown significant tumor suppression activity in various tumor models when administered alone or in combination, with high exposure levels observed in mouse studies [1]. Group 2: Impact on the Company - HSN002066C1 is the first clinical approval for Huason Yingnuo's innovative drug project, establishing a solid foundation for the company's strategy of combining innovation and generics [2]. - The company acknowledges that the drug development process is subject to various uncertainties, including technical, regulatory, and market competition factors, which may affect the clinical trial progress and eventual market approval [2].

Core Viewpoint - Chongqing Huasen Pharmaceutical Co., Ltd. announced that its subsidiary, Huasen Inno Biotech Co., Ltd., has received the Clinical Trial Approval Notification for the innovative drug HSN002066C1 from the National Medical Products Administration, marking a significant milestone in the company's drug development efforts [1]. Group 1: Drug Approval Details - Huasen Inno has been granted approval for HSN002066C1, a selective small molecule inhibitor of PARP7, intended for oral administration in the treatment of advanced malignant solid tumors [1]. - The drug has shown high exposure levels in mice and significant tumor suppression activity in various tumor models, either as a monotherapy or in combination therapy [1]. Group 2: Impact on the Company - HSN002066C1 is the first Class 1 innovative drug project approved for clinical trials by Huasen Inno, establishing a solid foundation for the company's strategy of combining innovation and generics [1]. - The company acknowledges that the drug development process is subject to various uncertainties, including technical, regulatory, and market competition factors, which may affect the clinical trial progress and the eventual market approval [1].

Group 1 - The company Huason Pharmaceutical announced that its subsidiary, Chongqing Huason Inno Biotech Co., Ltd., received approval from the National Medical Products Administration for the clinical trial of HSN002066C1 tablets in two specifications [1] - This approval marks a significant step in the company's research and development efforts in the pharmaceutical sector [1] - The clinical trial approval is expected to enhance the company's product pipeline and potentially lead to new market opportunities [1]

Core Viewpoint - Huason Pharmaceutical's subsidiary, Chongqing Huason Inno Biotech Co., Ltd., has received approval from the National Medical Products Administration for the clinical trial of HSN002066C1 tablets, marking a significant milestone for the company's innovative drug development [1]. Group 1 - HSN002066C1 tablets are the first Class 1 innovative drug project approved for clinical trials by Huason Inno, highlighting the company's commitment to innovation in drug development [1]. - The approval is expected to lay a solid foundation for the company's strategy of combining innovation and generics in its development approach [1].

Core Viewpoint - Huason Pharmaceutical's subsidiary, Chongqing Huason Yino Biotechnology Co., Ltd., has received approval from the National Medical Products Administration for clinical trials of HSN002066C1 tablets, marking a significant milestone in the company's innovative drug development strategy [1] Group 1: Product Development - HSN002066C1 tablets, a selective PARP7 small molecule inhibitor, are developed independently by Huason Yino and possess complete intellectual property rights [1] - The drug is intended for oral administration in the treatment of advanced malignant solid tumors, demonstrating significant tumor suppression activity in various tumor models [1] - HSN002066C1 is the first Class 1 innovative drug project approved for clinical trials by Huason Yino, establishing a solid foundation for the company's strategy of combining innovation and generics [1]

Core Viewpoint - Huason Pharmaceutical (002907.SZ) announced that its subsidiary, Chongqing Huason Yino Biotechnology Co., Ltd. (referred to as "Huason Yino"), has received the Clinical Trial Approval Notice from the National Medical Products Administration for the HSN002066C1 tablet in two specifications [1] Group 1 - HSN002066C1 tablet (with free base HSN002B015) is a selective small molecule inhibitor of poly(ADP-ribose) polymerase 7 (PARP7) developed independently by Huason Yino, with full ownership of intellectual property rights [1] - The clinical application of HSN002066C1 is intended for the treatment of patients with advanced malignant solid tumors [1] - HSN002066C1 is characterized as a potent and highly selective PARP7 inhibitor, showing significant tumor suppression activity in various tumor models when administered alone or in combination [1]

Core Viewpoint - Huason Pharmaceutical's subsidiary, Chongqing Huason Inno Biotech Co., Ltd., has received approval from the National Medical Products Administration for clinical trials of HSN002066C1 tablets, a selective PARP7 inhibitor for treating advanced malignant solid tumors [1] Group 1 - HSN002066C1 tablets, with the free base HSN002B015, are independently developed by Huason Inno and fully owned in terms of intellectual property rights [1] - The drug is intended for oral administration and has shown significant tumor suppression activity in various tumor models when used alone or in combination [1] - HSN002066C1 is characterized as a potent and highly selective PARP7 inhibitor, demonstrating high exposure levels in mice [1]

Core Viewpoint - Huason Pharmaceutical announced that HSN002066C1 tablets have received the "Drug Clinical Trial Approval Notice" from the National Medical Products Administration, allowing clinical trials for advanced malignant solid tumors [1] Group 1 - The drug HSN002066C1 is classified as a Class 1.1 new drug [1] - The application numbers for the approval are CXHL2501398 and CXHL2501399 [1] - The indication for HSN002066C1 is for advanced malignant solid tumors, and it is approved for monotherapy in clinical trials [1]